Cleveland-Cliffs Inc (CLF) requires closer examination

While Cleveland-Cliffs Inc has underperformed by -0.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CLF fell by -52.61%, with highs and lows ranging from $16.47 to $5.63, whereas the simple moving average fell by -30.40% in the last 200 days.

On May 29, 2025, Jefferies Downgraded Cleveland-Cliffs Inc (NYSE: CLF) to Hold. A report published by Goldman on December 02, 2024, Initiated its previous ‘Buy’ rating for CLF. Seaport Research Partners also Upgraded CLF shares as ‘Buy’, setting a target price of $16.50 on the company’s shares in a report dated August 27, 2024. JP Morgan June 11, 2024d the rating to Neutral on June 11, 2024, and set its price target from $23 to $17. Jefferies initiated its ‘Buy’ rating for CLF, as published in its report on May 20, 2024. Wolfe Research’s report from April 09, 2024 suggests a price prediction of $18 for CLF shares, giving the stock a ‘Underperform’ rating. Citigroup also rated the stock as ‘Neutral’.

Analysis of Cleveland-Cliffs Inc (CLF)

Further, the quarter-over-quarter decrease in sales is -10.96%, showing a negative trend in the upcoming months.

One of the most important indicators of Cleveland-Cliffs Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -17.57% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.64, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can also provide valuable insight into volatility, and CLF is recording 28.60M average volume. On a monthly basis, the volatility of the stock is set at 6.47%, whereas on a weekly basis, it is put at 4.86%, with a loss of -5.66% over the past seven days. Furthermore, long-term investors anticipate a median target price of $8.07, showing growth from the present price of $7.17, which can serve as yet another indication of whether CLF is worth investing in or should be passed over.

How Do You Analyze Cleveland-Cliffs Inc Shares?

Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.86%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 74.11% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

CLF shares are owned by institutional investors to the tune of 74.11% at present.

Hot this week

Should investors be concerned about Beyond Meat Inc (BYND)?

While Beyond Meat Inc has overperformed by 1.99%, investors...

Is NGL Energy Partners LP (NGL) worth investing in despite its overvalued state?

While NGL Energy Partners LP has overperformed by 0.47%,...

Are Coherus Oncology Inc (CHRS) shares a good deal now?

While Coherus Oncology Inc has overperformed by 8.84%, investors...

Century Therapeutics Inc (IPSC) requires closer examination

While Century Therapeutics Inc has overperformed by 2.25%, investors...

Vivid Seats Inc (SEAT) shows promising results

While Vivid Seats Inc has underperformed by -2.54%, investors...

Topics

Should investors be concerned about Beyond Meat Inc (BYND)?

While Beyond Meat Inc has overperformed by 1.99%, investors...

Is NGL Energy Partners LP (NGL) worth investing in despite its overvalued state?

While NGL Energy Partners LP has overperformed by 0.47%,...

Are Coherus Oncology Inc (CHRS) shares a good deal now?

While Coherus Oncology Inc has overperformed by 8.84%, investors...

Century Therapeutics Inc (IPSC) requires closer examination

While Century Therapeutics Inc has overperformed by 2.25%, investors...

Vivid Seats Inc (SEAT) shows promising results

While Vivid Seats Inc has underperformed by -2.54%, investors...

What was Verrica Pharmaceuticals Inc (VRCA)’s performance in the last session?

While Verrica Pharmaceuticals Inc has overperformed by 3.84%, investors...

Is Trump Media & Technology Group Corp (DJT) a good investment opportunity?

While Trump Media & Technology Group Corp has overperformed...

Vir Biotechnology Inc (VIR) presents a great opportunity, but the stock is slightly overvalued

While Vir Biotechnology Inc has overperformed by 0.57%, investors...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.